141 related articles for article (PubMed ID: 12196358)
1. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide.
Balzarotti M; Spina M; Sarina B; Magagnoli M; Castagna L; Milan I; Ripa C; Latteri F; Bernardi D; Bertuzzi A; Nozza A; Roncalli M; Morenghi E; Tirelli U; Santoro A
Ann Oncol; 2002 Sep; 13(9):1341-6. PubMed ID: 12196358
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalation of CHOP in non-Hodgkin's lymphoma.
Santoro A; Balzarotti M; Tondini C; Zanini M; Giardini R; Latteri F; Rampinelli I; Bufalino R
Ann Oncol; 1999 May; 10(5):519-25. PubMed ID: 10416000
[TBL] [Abstract][Full Text] [Related]
4. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma.
Itoh K; Ohtsu T; Wakita H; Igarashi T; Ishizawa K; Onozawa Y; Fujii H; Minami H; Sasaki Y
Ann Oncol; 2000 Oct; 11(10):1241-7. PubMed ID: 11106111
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
[TBL] [Abstract][Full Text] [Related]
7. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
9. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
Bessell EM; Burton A; Haynes AP; Glaholm J; Child JA; Cullen MH; Davies JM; Smith GM; Ellis IO; Jack A; Jones EL;
Ann Oncol; 2003 Feb; 14(2):258-67. PubMed ID: 12562653
[TBL] [Abstract][Full Text] [Related]
10. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Portlock CS; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz AD; O'Brien JP; Moskowitz C; Norton L; Yahalom J; Straus DJ; Bertino JR
Ann Oncol; 2004 Oct; 15(10):1495-503. PubMed ID: 15367410
[TBL] [Abstract][Full Text] [Related]
11. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
14. VB-CHEP chemotherapy regimen for aggressive non-Hodgkin's lymphomas.
Yalçin S; Kars A; Ozişik Y; Tekuzman G; Ozyilkan O; Celik I; Barişta I; Güllü I; Güler N; Baltali E; Firat D
Eur J Haematol; 1998 Oct; 61(4):261-5. PubMed ID: 9820633
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
Kinoshita T; Hotta T; Tobinai K; Kobayashi T; Ishizuka N; Tomonaga M; Sai T; Ohno Y; Kasai M; Ogura M; Mikuni C; Toki H; Sano M; Masaki Y; Ohtsu T; Matsuno Y; Takenaka T; Shirakawa S; Shimoyama M;
Int J Hematol; 2004 Nov; 80(4):341-50. PubMed ID: 15615259
[TBL] [Abstract][Full Text] [Related]
16. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.
Meyer RM; Gyger M; Langley R; Lespérance B; Caplan SN
Leuk Lymphoma; 1998 Aug; 30(5-6):591-600. PubMed ID: 9711921
[TBL] [Abstract][Full Text] [Related]
18. Dose density and dose intensity: where does CHOP go from here?
Portlock CS
Ann Oncol; 2002 Sep; 13(9):1329-30. PubMed ID: 12196356
[No Abstract] [Full Text] [Related]
19. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
Talbot SM; Westerman DA; Grigg AP; Toner GC; Wolf M; Bishop J; McKendrick J; Zalcberg J; Levi J; Fox RM; Green MD
Ann Oncol; 1999 Aug; 10(8):907-14. PubMed ID: 10509151
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
